AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to ...

The Final Investment Decision aims to increase capacity to approximately 21 BCM annually through new wells and platform ...

Chevron has taken a final investment decision to expand production at Israel’s Leviathan gas field, significantly increasing ...

Objective: To compare and analyze the differences in vaginal microecological characteristics between populations with ...

ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...

A'dor Kitchen and Cocktail, which recently opened a new Third Ward location in the former Turkey Leg Hut, is now serving a ...

Salah’s ongoing AFCON heartbreak, bested once again by Senegal in the semis, probably signals an early end to his 2026 Ballon ...

The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...

The Jerusalem Post Group, in collaboration with the Texas-Israel Alliance (TIA), announced the "Unicorn Rodeo" conference in ...

Beverly Geiger Bonnheim was 17 when the Ku Klux Klan bombed her synagogue in 1967. This weekend, at 75, she watched it burn ...

Almost all Missouri license offices are privately owned and contracted with the DOR. The only other DMV within Kansas City ...

In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients ...